{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:42:43Z","timestamp":1777927363257,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Nigeria has adopted routine screening of pregnant women for hepatitis B virus (HBV) as part of the interventions to eliminate its vertical transmission. However, there is a dearth of evidence on the coverage of routine antenatal HBV screening as recommended in the national guidelines. This study examined the antenatal HBV screening rate and the positivity rate compared with syphilis and HIV. We conducted a descriptive analysis of the 2019 national HIV\/AIDS health sector data. The study included approximately 2.8 million pregnant women who received antenatal care (ANC) in over 6000 health facilities providing prevention of mother-to-child transmission of HIV services in Nigeria. Of the ANC clients, 0.2 million (7.2%) were screened for HBV. At the zonal level, the South West had the highest HBV screening rate (19%), while the lowest rate was in the North East (2.5%). The percentage of pregnant women screened for HBV was lower than those screened for syphilis (16.3%) and HIV (90.3%). Among those screened for HBV, the positivity rate was 5%. The HBV positivity rate ranged from 8.5% in the North Central zone to 1.3% in the South East zone. The positivity rates for syphilis and HIV were 0.4% and 0.5%, respectively. Our results indicate a low antenatal HBV screening rate and a wide disparity compared with HIV and syphilis. This finding highlights the need to understand and address the barriers affecting routine antenatal HBV screening and to strengthen the integration of HBV services into the HIV program in Nigeria.<\/jats:p>","DOI":"10.1177\/09564624211035922","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T07:56:48Z","timestamp":1628841408000},"page":"1290-1297","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Antenatal hepatitis B screening in Nigeria: A comparative analysis with syphilis and HIV"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0864-6901","authenticated-orcid":false,"given":"Babayemi O","family":"Olakunde","sequence":"first","affiliation":[{"name":"Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria"},{"name":"Center for Translation and Implementation Research, University of Nigeria, Nsukka, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A","family":"Adeyinka","sequence":"additional","affiliation":[{"name":"Department of Public Health, National AIDS and STI Control Programme, Federal Ministry of Health, Abuja, Nigeria"},{"name":"Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinwendu D","family":"Ndukwe","sequence":"additional","affiliation":[{"name":"Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria"},{"name":"African Institute of Health Policy and Health Systems, Abakaliki, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tolulope T","family":"Oladele","sequence":"additional","affiliation":[{"name":"Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidayat B","family":"Yahaya","sequence":"additional","affiliation":[{"name":"Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olugbengba A","family":"Ijaodola","sequence":"additional","affiliation":[{"name":"Department of Public Health, National AIDS and STI Control Programme, Federal Ministry of Health, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"bibr1-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"bibr2-09564624211035922","volume-title":"Nigeria HIV\/AIDS Indicator and Impact Survey (NAIIS) 2018: Final Report","author":"Federal Ministry of Health","year":"2019"},{"key":"bibr3-09564624211035922","first-page":"1","volume":"9","author":"Ezeilo MC","year":"2018","journal-title":"Virology (Auckl)"},{"key":"bibr4-09564624211035922","volume-title":"National Guidelines for the Prevention, Care and Treatment of Viral Hepatitis B & C in Nigeria","author":"National AIDS\/STIs Control Programme, Federal Ministry of Health","year":"2016"},{"issue":"6","key":"bibr5-09564624211035922","first-page":"407","volume":"61","author":"Eke CB","year":"2015","journal-title":"J Trop Pediatr"},{"key":"bibr6-09564624211035922","doi-asserted-by":"publisher","DOI":"10.3109\/00016349.2010.482580"},{"key":"bibr7-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30279-6"},{"key":"bibr8-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420953722"},{"key":"bibr9-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-185"},{"key":"bibr10-09564624211035922","volume-title":"Prevention of Mother-To-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy","author":"World Health Organization","year":"2020"},{"key":"bibr11-09564624211035922","volume-title":"Global Health Sector Strategy on Viral Hepatitis 2016-2021:Towards Ending Viral Hepatitis","author":"World Health Organization","year":"2016"},{"key":"bibr12-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7095-4"},{"key":"bibr13-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.041"},{"key":"bibr14-09564624211035922","doi-asserted-by":"publisher","DOI":"10.5365\/wpsar.2017.8.3.005"},{"key":"bibr15-09564624211035922","volume-title":"Regional framework for the triple elimination of mother-to-child transmission of hiv, hepatitis B and syphilis in Asia and the Pacific, 2018\u20132030","author":"World Health Organization Regional Office for the Western Pacific","year":"2018"},{"key":"bibr16-09564624211035922","unstructured":"National AIDS\/STIs Control Programme, Federal Ministry of Health. National strategic plan for the control of viral hepatitis in Nigeria (2016-2020). Abuja, 2016."},{"key":"bibr17-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1177\/0956462416665027"},{"key":"bibr18-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1177\/1403494817744988"},{"key":"bibr19-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2015.04.014"},{"key":"bibr20-09564624211035922","doi-asserted-by":"publisher","DOI":"10.3109\/01443615.2012.711389"},{"key":"bibr21-09564624211035922","unstructured":"The World Bank. Population, total- Nigeria, https:\/\/data.worldbank.org\/indicator\/SP.POP.TOTL?locations=NG (2020, accessed 11 Janaury, 2021)."},{"key":"bibr22-09564624211035922","unstructured":"United Nations Children\u2019s Fund. Situation of Women and Children in Nigeria, https:\/\/www.unicef.org\/nigeria\/situation-women-and-children-nigeria (accessed 11 July, 2021)."},{"key":"bibr23-09564624211035922","volume-title":"Nigeria Demographic and Health Survey 2018","author":"National Population Commission, ICF","year":"2019"},{"key":"bibr24-09564624211035922","unstructured":"National AIDS & STIs Control Programme, Federal Ministry of Health. 2019 annual report on HIV\/AIDS health sector response in Nigeria. Abuja, 2019."},{"key":"bibr25-09564624211035922","unstructured":"Hepatitis B Foundation. The journey to hepatitis elimination in Nigeria, https:\/\/www.hepb.org\/blog\/journey-hepatitis-elimination-nigeria\/ (2020, accessed 13 January 2021)."},{"key":"bibr26-09564624211035922","doi-asserted-by":"publisher","DOI":"10.5897\/JPHE2017.0978"},{"key":"bibr27-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2772-3"},{"key":"bibr28-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2767-0"},{"key":"bibr29-09564624211035922","volume-title":"Viral Hepatitis Services Facility Directory in nigeria: Resource for Improving Accessibility to Viral Hepatitis Services","author":"Federal Ministry of Health","year":"2018"},{"key":"bibr30-09564624211035922","doi-asserted-by":"publisher","DOI":"10.5210\/ojphi.v6i2.5287"},{"key":"bibr31-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy028"},{"key":"bibr32-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(15)00056-X"},{"key":"bibr33-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2015.04.004"},{"key":"bibr34-09564624211035922","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/coverages?c=NGA (2020, accessed 11 January, 2021)."},{"key":"bibr35-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3191-9"},{"key":"bibr36-09564624211035922","first-page":"1","volume":"8","author":"Dayyab FM","year":"2020","journal-title":"Ther Adv Vaccin Immunother"},{"key":"bibr37-09564624211035922","doi-asserted-by":"publisher","DOI":"10.4103\/1119-3077.151035"},{"key":"bibr38-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.11.009"},{"key":"bibr39-09564624211035922","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.2764"},{"key":"bibr40-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-119"},{"key":"bibr41-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.05.1032"},{"key":"bibr42-09564624211035922","doi-asserted-by":"publisher","DOI":"10.1007\/s13224-012-0164-6"},{"key":"bibr43-09564624211035922","doi-asserted-by":"publisher","DOI":"10.4103\/2141-9248.144925"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624211035922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624211035922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624211035922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:42:09Z","timestamp":1777675329000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624211035922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":43,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/09564624211035922"],"URL":"https:\/\/doi.org\/10.1177\/09564624211035922","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}